Castleview Partners’s Bio-Techne TECH Stock Holding History

Castleview Partners’s Portfolio TECH Stock Details TECH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-55	Closed	-$3.74K	–	893
2023 Q3	$3.74K	Buy	+55	New	+$4.34K	﹤0.01%	508

Other funds holding TECH

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

DDC

DF Dent & Co Baltimore, Maryland $5.27B AUM 7.89% 1-Year Est. Return

Castleview Partners's TECH Position: Q4 2023 in Review

Castleview Partners sold out of Bio-Techne (TECH) in Q4 2023, closing a stake of 55 shares — an estimated $3.74K sold.

Castleview Partners first reported a position in TECH in Q3 2023 and held it in 1 quarter. The position peaked at $3.74K in Q3 2023. 531 funds tracked by Wall St. Rank hold TECH as of Q4 2023.

Castleview Partners reported no remaining Bio-Techne position as of Q4 2023 after selling out during the quarter.
Castleview Partners sold 55 Bio-Techne shares in Q4 2023, an estimated $3.74K.
Castleview Partners first reported a position in Bio-Techne in Q3 2023 and held it in 1 quarter.
Castleview Partners's Bio-Techne position peaked at $3.74K in Q3 2023.
531 funds tracked by Wall St. Rank held Bio-Techne as of Q4 2023.

Based on Castleview Partners's 13F filing for Q4 2023, filed 5 Feb 2024.